1674 Risk of Complications of Perioperative Mitomycin (Mmc) Among Bladder Cancer Patients Undergoing Endoscopic Tumor Resection

Filson, Christopher P.; Montgomery, Jeffrey S.; Dailey, Stephen; Crossley, Heather; Al-Attar, Paul M.; He, Chang; Lentz, Heidi; Tallman, Christopher; Weizer, Alon Z.

doi:10.1016/j.juro.2012.02.1532

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Allergic cystitis has been reported in up to 10% of patients undergoing immediate intravesical therapy, with the most severe cases ultimately requiring cystectomy. 19 Other barriers to the use of mitomycin include a drug shortage, a belief that this therapy is not effective, or that giving the medication presents too great a risk. Continued provider education efforts and improved systems for delivering the medication are needed to expand the use of this therapy.…”

Section: Perioperative Intravesical Chemotherapymentioning

confidence: 99%

Quality Indicators in the Management of Bladder Cancer

Montgomery¹,

Miller²,

Weizer³

2013

J Natl Compr Canc Netw

View full text Add to dashboard Cite

Bladder cancer is predominantly seen in elderly patients. With the aging United States population, the incidence and prevalence of bladder cancer are on the rise, heightening the relevance of this disease as a public health issue. Despite having one of the greatest average cancer treatment costs per patient, improvements in disease-specific survival have been subtle. Clinical guidelines based predominantly on expert opinion and randomized controlled studies offer some guidance, but adherence to these guidelines is lacking. Building awareness of quality indicators to optimize patient care represents an opportunity to improve bladder cancer outcomes. Although quality indicators exist for other disease states, widely accepted quality indicators for the management of bladder cancer have not yet been established. This article proposes an initial set of quality indicators for both non-muscle-invasive and muscle-invasive bladder cancer based on established clinical guidelines and the available literature. (JNCCN 2013;11:492-500) NCCN: Continuing Education Accreditation StatementThis activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer. There is no fee for this article. No commercial support was received for this article. The National Comprehensive Cancer Network (NCCN) is accredited by the ACCME to provide continuing medical education for physicians.NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center`s Commission on Accreditation.This activity is approved for 1.0 contact hour. Approval as a provider refers to recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.All clinicians completing this activity will be issued a certificate of participation. To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 70% minimum passing score and complete the evaluation at http://education.nccn.org/ node/17316; and 4) view/print certificate.Release date: April 11, 2013; Expiration date: April 11, 2014. Learning ObjectivesUpon completion of this activity, participants will be able to:• Identify proposed quality indicators for non-muscleinvasive and muscle-invasive bladder cancer.• Discuss treatment recommendations and guidelines for non-muscle-invasive and muscle-invasive bladder cancer. Ms. Harrold has disclosed that she has no relevant financial relationships. Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information OperationsMs. Grego...

show abstract

Section: Perioperative Intravesical Chemotherapymentioning

confidence: 99%